US Drug Importation: Hard To See Path Forward, Former HHS Adviser Says
Former drug pricing advisor John O’Brien discusses next steps for Administration policies around importation and international reference pricing during a speech to the Academy of Managed Care Pharmacy.
You may also be interested in...
HHS Secretary Alex Azar says that reshaping Administration’s upcoming proposed rule would drive Medicare Part B drug prices even lower than previously projected. As Part B drug costs are being blamed for higher premiums, the policy revisions are at OMB, but plan would reemerge as "a notice of proposed rulemaking if that comes out,” Azar said.
“We’re out of time for ideas," Domestic Policy Council Director Joe Grogan says. Trump administration is pushing hard to get the Senate drug pricing bill through Congress quickly and score a major victory for the President.
Price inflation rebates are the linchpin of the legislation’s Democratic support, Sen. Chuck Grassley, R-IA, argues. But to many Republicans, they sound too much like price controls.